Cara Therapeutics Financial Statements (CARA)
|
|
|
|
Report date
|
|
|
01.03.2022 |
06.03.2023 |
06.03.2024 |
11.03.2025 |
31.03.2026 |
|
08.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
23.0 |
41.9 |
21.0 |
7.14 |
0.000 |
|
2.57 |
|
Operating Income, bln rub |
|
|
-89.1 |
-87.5 |
-121.5 |
-58.4 |
-26.7 |
|
-33.8 |
|
EBITDA, bln rub |
? |
|
-88.2 |
-83.8 |
-117.7 |
-62.6 |
-26.7 |
|
-33.4 |
|
Net profit, bln rub |
? |
|
-88.2 |
-83.4 |
-118.5 |
-70.9 |
-18.2 |
|
-20.1 |
|
|
OCF, bln rub |
? |
|
-60.1 |
-78.7 |
-92.1 |
-60.9 |
-23.5 |
|
-24.7 |
|
CAPEX, bln rub |
? |
|
0.039 |
0.043 |
2.38 |
1.05 |
0.000 |
|
0.000 |
|
FCF, bln rub |
? |
|
-60.1 |
-78.8 |
-94.5 |
-62.0 |
-23.5 |
|
-24.7 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
0.00% |
|
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
112.1 |
122.1 |
136.3 |
64.9 |
26.7 |
|
28.8 |
|
Cost of production, bln rub |
|
|
1.55 |
7.27 |
6.17 |
0.620 |
0.000 |
|
0.000 |
|
R&D, bln rub |
|
|
82.7 |
91.9 |
108.5 |
32.8 |
18.0 |
|
22.6 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.604 |
8.47 |
0.000 |
|
2.87 |
|
|
Assets, bln rub |
|
|
247.1 |
182.2 |
125.8 |
43.8 |
32.1 |
|
25.8 |
|
Net Assets, bln rub |
? |
|
227.5 |
158.8 |
57.1 |
-4.59 |
20.9 |
|
14.5 |
|
Debt, bln rub |
|
|
3.67 |
1.92 |
43.2 |
0.000 |
0.201 |
|
0.174 |
|
Cash, bln rub |
|
|
167.0 |
145.4 |
100.8 |
37.9 |
30.8 |
|
25.0 |
|
Net debt, bln rub |
|
|
-163.4 |
-143.5 |
-57.6 |
-37.9 |
-30.6 |
|
-24.8 |
|
|
Ordinary share price, rub |
|
|
438.5 |
|
|
18.4 |
|
|
5.32 |
|
Number of ordinary shares, mln |
|
|
50.7 |
53.7 |
54.1 |
45.6 |
7 419 |
|
9 381 |
|
|
Market cap, bln rub |
|
|
22 239 |
0 |
0 |
838 |
0 |
|
49 909 |
|
EV, bln rub |
? |
|
22 076 |
-143 |
-58 |
800 |
-31 |
|
49 884 |
|
Book value, bln rub |
|
|
228 |
159 |
57 |
-5 |
21 |
|
14 |
|
|
EPS, rub |
? |
|
-1.74 |
-1.55 |
-2.19 |
-1.55 |
0.00 |
|
0.00 |
|
FCF/share, rub |
|
|
-1.19 |
-1.47 |
-1.75 |
-1.36 |
0.00 |
|
0.00 |
|
BV/share, rub |
|
|
4.49 |
2.96 |
1.05 |
-0.10 |
0.00 |
|
0.00 |
|
|
EBITDA margin, % |
? |
|
-383.0% |
-200.2% |
-561.1% |
-877.1% |
|
|
-1 299% |
|
Net margin, % |
? |
|
-383.0% |
-199.2% |
-565.2% |
-993.0% |
|
|
-782.9% |
|
FCF yield, % |
? |
|
-0.27% |
|
|
-7.40% |
|
|
-0.05% |
|
ROE, % |
? |
|
-38.8% |
-52.5% |
-207.6% |
1 543% |
-87.0% |
|
-138.7% |
|
ROA, % |
? |
|
-35.7% |
-45.8% |
-94.2% |
-161.7% |
-56.8% |
|
-77.9% |
|
|
P/E |
? |
|
-252.2 |
0.00 |
0.00 |
-11.8 |
0.00 |
|
-2 482 |
|
P/FCF |
|
|
-369.9 |
0.00 |
0.00 |
-13.5 |
0.00 |
|
-2 023 |
|
P/S |
? |
|
965.7 |
0.00 |
0.00 |
117.4 |
|
|
19 427 |
|
P/BV |
? |
|
97.7 |
0.00 |
0.00 |
-182.4 |
0.00 |
|
3 515 |
|
EV/EBITDA |
? |
|
-250.3 |
1.71 |
0.49 |
-12.8 |
1.14 |
|
-1 495 |
|
Debt/EBITDA |
|
|
1.85 |
1.71 |
0.49 |
0.61 |
1.14 |
|
0.74 |
|
|
R&D/CAPEX, % |
|
|
212 054% |
213 672% |
4 569% |
3 136% |
|
|
|
|
|
CAPEX/Revenue, % |
|
|
0.17% |
0.10% |
11.3% |
14.7% |
|
|
0 |
|
| Cara Therapeutics shareholders |
